Although BRAF inhibitors have been broadly effective in treating melanoma patients who have the BRAF V600E mutation [25,26], a much smaller portion of BRAF-mutated patients with other cancer types, such as colorectal cancer (CRC), respond to the same treatment [27]. This evidence concerns the gene BRAF and colorectal cancer.